Buerger’s Disease (BD) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Buerger’s Disease (BD) or Thromboangiitis obliterans (TAO) is a nonatherosclerotic, segmental inflammatory disease that most commonly affects the small and medium-sized arteries and veins in the upper and lower extremities. In the characteristic acute-phase lesion, in association with occlusive cellular thrombosis, the acute inflammation involving all layers of the vessel wall led TAO to be classified as a vasculitis. There is no consistent pattern in HLA haplotypes among patients with Buerger’s disease. However, in the European nations, there was a preponderance of HLA-A9 and HLA-B5 antigens.
The acute-phase lesion is
characterized by acute inflammation involving all coats of the vessel wall,
especially of the veins, in association with occlusive thrombosis.
Intermediate phase in
which there is a progressive organization of the occlusive thrombus in the
arteries and veins. Chronic phase or end-stage lesion is characterized by
organization of the occlusive thrombus with extensive recanalization, prominent
vascularization of the media, and adventitial and perivascular fibrosis.
In the year 2019, the
overall incidence of cases of Buerger’s disease is reported to be 12.5 to 28
cases per 100,000 population in the USA, however, the numbers are high in
European and APAC populations.
The competitive
landscape of Buerger’s Disease (BD) includes country-specific approved as well
as pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are being tracked and supplemented with analyst
commentary.
KOLs insights of Buerger’s Disease (BD) across
8 MM market from the centre of Excellence/ Public/ Private hospitals participated
in the study. Insights around current treatment landscape, epidemiology,
clinical characteristics, future treatment paradigm, and Unmet needs.
Buerger’s
Disease (BD) Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 AMB-301 Ambulero
Inc. Phase 1
2 Allogeneic Mesenchymal Stem Cells Stempeutics Research Pvt Ltd Phase
2
3 CLBS12 Caladrius
Biosciences, Inc. Phase 2
Comments
Post a Comment